| Factor Information | |
|---|---|
| Data ID | 4002 |
| Factor | TIMP2(Tissue Inhibitor of Metalloproteinases 2) |
| Description | Urinary concentrations of tissue inhibitor of metalloproteinases-2 and insulin-like growth factor binding protein 7 were significantly lower in patients with a congenital heart disease when compared to subjects without a diagnosis. |
| Biomarker | YES |
| Classification | E2 (physiological factor - biochemical index) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To determine if young adults with congenital heart disease have differences in the baseline concentration of urinary tubular biomarkers when compared to healthy young adults. |
| p Value | 0.009 |
| Conclusion | Our study suggest young adults with congenital heart disease may have subclinical kidney dysfunction. Lower levels of IGFBP7 and TIMP2 may indicate an impaired ability to respond to injury, while higher levels of kidney injury molecule-1 may reflect early tubular injury. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 744 |
| CHD Type | isolated CHD |
| CHD Subtype | D-TGA/BAV/TOF/CoA/NA/AVSD/AS/VSD |
| Reference | |
|---|---|
| PMID | 31793232 |
| Year | 2019 |
| Title | Baseline tubular biomarkers in young adults with congenital heart disease as compared to healthy young adults: Detecting subclinical kidney injury |
| Sample | ||
|---|---|---|
| Population | young adults | |
| Source | patients' blood | |
| Region | Pittsburgh, USA | |
| Method | Urinary tissue inhibitor of metalloproteinases-2, insulin-like growth factor binding protein 7 and the product of tissue inhibitor of metalloproteinases-2 and in- sulin-like growth factor binding protein 7 ([tissue inhibitor of metal- loproteinases-2]•[insulin-like growth factor binding protein 7]) was measured with the NephroCheckTM Test (Astute Medical, San Diego, CA, USA) | |
| Race | American | |
| Disease History | N/A | |
| Treatment History | medication with Metoprolol/Aspirin/Warfarin/Furosemide, etc | |
| Group | young adults with CHD(Treatment) | health young adults(Control) |
| Number | 30 | 30 |
| Age | 28 (26-31) years | 27 (22-30) years |
| Gender (Male: Female) | male:66.7% | male:56.7% |
| Marker Level | 2.50 (2.00-3.94)(ng/ml) | 3.70 (2.85-5.23)(ng/ml) |
